Clene Inc. (CLNN) AI Stock Analysis

Clene Inc. is a clinical-stage pharmaceutical company based in Salt Lake City, Utah, focused on clean-surfaced nanotechnology therapeutics. Its lead drug candidate, CNM-Au8, is undergoing a Phase 2/3 trial for amyotrophic lateral sclerosis (ALS), Phase 2 trials for chronic optic neuropathy, and planned Phase 2 trials for Parkinson's Disease. Its pipeline also includes CNM-AgZn17 for infectious diseases and wound healing, CNM-ZnAg for antiviral and antibacterial uses, and CNM-PtAu7 for oncology applications. Additionally, Clene offers dietary supplements such as rMetx and KHC46 using zinc-silver and gold nanoparticles.

Clene's annual revenue declined from $723,000 in FY2021 to $200,000 in FY2025, reflecting a 5-year revenue CAGR of -0.6% from FY2020 to FY2025. Gross margin was 78.5% in FY2025, down from 94.5% in FY2022. Net loss improved from -$49.5M in FY2023 to -$26.2M in FY2025, alongside an operating margin of -11541.5%. R&D expense decreased to $14.0M in FY2025 from $31.9M in FY2022. For the trailing twelve months ended June 30, 2026, revenue stood at $197,000 with an EPS of -$3.52, while quarterly revenue growth reached 233.3% year-over-year.

As of June 30, 2026, Clene had $9.7M in cash and short-term investments and $22.3M in total debt, leading to net debt of $12.7M. Total assets were $23.0M, the current ratio was 3.07, and shareholders' equity was -$24.8M. In FY2025, operating cash flow was -$18.5M, free cash flow was -$18.6M, and capital expenditures were $39,000. Over five years, the company's share count increased by 297.5%.

At a last close of $3.10 on October 16, 2026, Clene had a market capitalization of $44.1M and an enterprise value of $73.7M. The stock trades at a price-to-sales multiple of 223.7x and an EV-to-revenue multiple of 373.9x, compared to a median price-to-sales multiple of 0.7x for its US-listed Consumer Defensive peers. Clene's shares fell 62.4% over the past year and 97.5% over five years, while the S&P 500 (SPY) returned 16.8% and 83.0% over those respective periods.

Five Wall Street analysts cover Clene, with 4 Strong Buy ratings and 1 Buy rating. The mean price target is $32.20, which is 938.7% above the last close of $3.10. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $249,400 and an EPS of -$2.62. For the next fiscal year, two analysts project revenue of $23.3M and an EPS of -$2.44. Over the last four quarters, the company beat EPS estimates 1 time. The next earnings date is November 12, 2026.

This page is an AI-written research summary of Clene Inc. (CLNN). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: CLNN income statement, CLNN balance sheet, CLNN key metrics, CLNN analyst forecast, CLNN chart. See the CLNN stock overview for the latest quote and news.